{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:28:37Z","timestamp":1789450117643,"version":"build-2803163510"},"reference-count":53,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,6,10]],"date-time":"2015-06-10T00:00:00Z","timestamp":1433894400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.jinf.2015.05.006","type":"journal-article","created":{"date-parts":[[2015,5,14]],"date-time":"2015-05-14T22:01:20Z","timestamp":1431640880000},"page":"326-337","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial"],"prefix":"10.1016","volume":"71","author":[{"given":"L.","family":"Marsay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Dold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.A.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.S.","family":"Rollier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Norheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Sadarangani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Shanyinde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Brehony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.J.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Haworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.P.","family":"Derrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.M.","family":"Feavers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Maiden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.J.","family":"Pollard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinf.2015.05.006_bib1","series-title":"Surveillance of invasive bacterial diseases in Europe 2007","author":"ECDC. European Centre for Disease Prevention and Control","year":"2010"},{"key":"10.1016\/j.jinf.2015.05.006_bib2","series-title":"Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Neisseria meningitidis, 2008","author":"Prevention CfDCa. Centers for Disease Control and Prevention","year":"2009"},{"key":"10.1016\/j.jinf.2015.05.006_bib3","unstructured":"England PH. Public Health England http:\/\/www.hpa.org.uk\/Topics\/InfectiousDiseases\/InfectionsAZ\/MeningococcalDisease\/EpidemiologicalData\/."},{"issue":"1","key":"10.1016\/j.jinf.2015.05.006_bib4","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1517\/14712598.2015.983897","article-title":"The capsular group B meningococcal vaccine, 4CMenB: clinical experience and potential efficacy","volume":"15","author":"Rollier","year":"2015","journal-title":"Expert Opin Biol Ther"},{"issue":"8346","key":"10.1016\/j.jinf.2015.05.006_bib5","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(83)90340-9","article-title":"Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis","volume":"2","author":"Finne","year":"1983","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jinf.2015.05.006_bib6","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/infdis\/126.5.514","article-title":"Immunologic response of man to group B meningococcal polysaccharide vaccines","volume":"126","author":"Wyle","year":"1972","journal-title":"J Infect Dis"},{"issue":"Suppl. 2","key":"10.1016\/j.jinf.2015.05.006_bib7","doi-asserted-by":"crossref","first-page":"B3","DOI":"10.1016\/j.vaccine.2009.04.071","article-title":"Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis","volume":"27","author":"Holst","year":"2009","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.jinf.2015.05.006_bib8","first-page":"195","article-title":"Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba","volume":"14","author":"Sierra","year":"1991","journal-title":"NIPH Ann"},{"issue":"8827","key":"10.1016\/j.jinf.2015.05.006_bib9","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/0140-6736(92)93086-3","article-title":"Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil","volume":"340","author":"de Moraes","year":"1992","journal-title":"Lancet"},{"issue":"17\u201318","key":"10.1016\/j.jinf.2015.05.006_bib10","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1016\/j.vaccine.2005.01.063","article-title":"MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain","volume":"23","author":"Oster","year":"2005","journal-title":"Vaccine"},{"issue":"8775","key":"10.1016\/j.jinf.2015.05.006_bib11","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/0140-6736(91)91961-S","article-title":"Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway","volume":"338","author":"Bjune","year":"1991","journal-title":"Lancet"},{"issue":"34","key":"10.1016\/j.jinf.2015.05.006_bib12","doi-asserted-by":"crossref","first-page":"5059","DOI":"10.1016\/j.vaccine.2012.05.051","article-title":"Evolution of immune response against Neisseria meningitidis B:14:P1.7,16 before and after the outer membrane vesicle vaccine MenBvac","volume":"30","author":"Caron","year":"2012","journal-title":"Vaccine"},{"issue":"40","key":"10.1016\/j.jinf.2015.05.006_bib13","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1016\/j.vaccine.2011.06.120","article-title":"Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand","volume":"29","author":"Arnold","year":"2011","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.jinf.2015.05.006_bib14","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1128\/CVI.13.4.486-491.2006","article-title":"The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB","volume":"13","author":"Martin","year":"2006","journal-title":"Clin Vaccine Immunol \u2013 CVI"},{"issue":"Suppl. 2","key":"10.1016\/j.jinf.2015.05.006_bib15","doi-asserted-by":"crossref","first-page":"B87","DOI":"10.1016\/j.vaccine.2012.01.033","article-title":"The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens","volume":"30","author":"Serruto","year":"2012","journal-title":"Vaccine"},{"issue":"23","key":"10.1016\/j.jinf.2015.05.006_bib16","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.vaccine.2013.03.034","article-title":"Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact","volume":"31","author":"Christensen","year":"2013","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.jinf.2015.05.006_bib17","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1006\/jmbi.1999.3144","article-title":"Crystal structure of an Fab fragment in complex with a meningococcal serosubtype antigen and a protein G domain","volume":"293","author":"Derrick","year":"1999","journal-title":"J Mol Biol"},{"issue":"4","key":"10.1016\/j.jinf.2015.05.006_bib18","doi-asserted-by":"crossref","first-page":"674","DOI":"10.3201\/eid1004.030247","article-title":"PorA variable regions of Neisseria meningitidis","volume":"10","author":"Russell","year":"2004","journal-title":"Emerg Infect Dis"},{"issue":"7","key":"10.1016\/j.jinf.2015.05.006_bib19","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.1128\/IAI.71.7.3775-3781.2003","article-title":"Antibody specificities and effect of meningococcal carriage in Icelandic teenagers receiving the Norwegian serogroup B outer membrane vesicle vaccine","volume":"71","author":"Wedege","year":"2003","journal-title":"Infect Immun"},{"issue":"6","key":"10.1016\/j.jinf.2015.05.006_bib20","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/0264-410X(94)90314-X","article-title":"Vaccine potential of meningococcal FrpB: studies on surface exposure and functional attributes of common epitopes","volume":"12","author":"Ala'Aldeen","year":"1994","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.jinf.2015.05.006_bib21","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1128\/iai.58.9.3036-3041.1990","article-title":"Monoclonal antibodies against the 70-kilodalton iron-regulated protein of Neisseria meningitidis are bactericidal and strain specific","volume":"58","author":"Pettersson","year":"1990","journal-title":"Infect Immun"},{"issue":"Pt 7","key":"10.1016\/j.jinf.2015.05.006_bib22","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1099\/mic.0.26131-0","article-title":"Antigenic diversity of meningococcal enterobactin receptor FetA, a vaccine component","volume":"149","author":"Thompson","year":"2003","journal-title":"Microbiology"},{"issue":"Pt 11","key":"10.1016\/j.jinf.2015.05.006_bib23","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1099\/13500872-142-11-3269","article-title":"Sequence variability of FrpB, a major iron-regulated outer-membrane protein in the pathogenic neisseriae","volume":"142","author":"van der Ley","year":"1996","journal-title":"Microbiology"},{"issue":"8","key":"10.1016\/j.jinf.2015.05.006_bib24","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1016\/j.micinf.2006.04.011","article-title":"Immunogenicity and structural characterisation of an in\u00a0vitro folded meningococcal siderophore receptor (FrpB, FetA)","volume":"8","author":"Kortekaas","year":"2006","journal-title":"Microbes Infect\/Institut Pasteur"},{"issue":"7","key":"10.1016\/j.jinf.2015.05.006_bib25","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1128\/CVI.00039-07","article-title":"Functional and specific antibody responses in adult volunteers in New Zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines","volume":"14","author":"Wedege","year":"2007","journal-title":"Clin Vaccine Immunol \u2013 CVI"},{"issue":"7","key":"10.1016\/j.jinf.2015.05.006_bib26","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1128\/IAI.66.7.3223-3231.1998","article-title":"Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial","volume":"66","author":"Wedege","year":"1998","journal-title":"Infect Immun"},{"issue":"12","key":"10.1016\/j.jinf.2015.05.006_bib27","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1128\/iai.56.12.3132-3138.1988","article-title":"Loss of transferrin receptor activity in Neisseria meningitidis correlates with inability to use transferrin as an iron source","volume":"56","author":"Tsai","year":"1988","journal-title":"Infect Immun"},{"issue":"18","key":"10.1016\/j.jinf.2015.05.006_bib28","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1016\/j.vaccine.2010.02.023","article-title":"Characterization of meningococcal serogroup B outer membrane vesicle vaccines from strain 44\/76 after growth in different media","volume":"28","author":"Tsolakos","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.jinf.2015.05.006_bib29","first-page":"81","article-title":"Outer membrane protein vesicle vaccines for meningococcal disease","volume":"66","author":"Frasch","year":"2001","journal-title":"Methods Mol Med"},{"issue":"2","key":"10.1016\/j.jinf.2015.05.006_bib30","doi-asserted-by":"crossref","first-page":"e56746","DOI":"10.1371\/journal.pone.0056746","article-title":"Use of a molecular decoy to segregate transport from antigenicity in the FrpB iron transporter from Neisseria meningitidis","volume":"8","author":"Saleem","year":"2013","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.jinf.2015.05.006_bib31","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.1128\/IAI.05806-11","article-title":"The iron-repressed, AraC-like regulator MpeR activates expression of fetA in Neisseria gonorrhoeae","volume":"79","author":"Hollander","year":"2011","journal-title":"Infect Immun"},{"issue":"10","key":"10.1016\/j.jinf.2015.05.006_bib32","doi-asserted-by":"crossref","first-page":"5955","DOI":"10.1128\/IAI.72.10.5955-5962.2004","article-title":"Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design","volume":"72","author":"Urwin","year":"2004","journal-title":"Infect Immun"},{"issue":"6","key":"10.1016\/j.jinf.2015.05.006_bib33","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1128\/CVI.00133-14","article-title":"Implications of differential age distribution of disease-associated meningococcal lineages for vaccine development","volume":"21","author":"Brehony","year":"2014","journal-title":"Clin Vaccine Immunol \u2013 CVI"},{"issue":"1","key":"10.1016\/j.jinf.2015.05.006_bib34","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1574-6976.2006.00056.x","article-title":"Multilocus sequence typing for global surveillance of meningococcal disease","volume":"31","author":"Brehony","year":"2007","journal-title":"FEMS Microbiol Rev"},{"issue":"Pt 4","key":"10.1016\/j.jinf.2015.05.006_bib35","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1099\/mic.0.2007\/014761-0","article-title":"Molecular epidemiology of meningococcal disease in England and Wales 1975\u20131995, before the introduction of serogroup C conjugate vaccines","volume":"154","author":"Russell","year":"2008","journal-title":"Microbiology"},{"key":"10.1016\/j.jinf.2015.05.006_bib36","series-title":"Invasive Neisseria meningitidis in Europe 2002","author":"EU-IBIS","year":"2003"},{"key":"10.1016\/j.jinf.2015.05.006_bib37","series-title":"Health protection weekly report","author":"HPA","year":"2013"},{"issue":"Pt 7","key":"10.1016\/j.jinf.2015.05.006_bib38","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1099\/jmm.0.46288-0","article-title":"Epidemiology of meningococcal disease in England and Wales 1993\/94 to 2003\/04: contribution and experiences of the Meningococcal Reference Unit","volume":"55","author":"Gray","year":"2006","journal-title":"J Med Microbiol"},{"issue":"2","key":"10.1016\/j.jinf.2015.05.006_bib39","first-page":"67","article-title":"Production, characterization and control of MenB-vaccine \u201cFolkehelsa\u201d: an outer membrane vesicle vaccine against group B meningococcal disease","volume":"14","author":"Fredriksen","year":"1991","journal-title":"NIPH Ann"},{"key":"10.1016\/j.jinf.2015.05.006_bib40","series-title":"Serogroup B and C serum bactericidal assays. Meningococcal vaccines","first-page":"289","author":"Borrow","year":"2001"},{"key":"10.1016\/j.jinf.2015.05.006_bib41","unstructured":"Sanders H, Norheim G, Chan H, Vipond C, Pollard AJ, Feavers I. Bactericidal FetA antibodies induced by an outer membrane vesicle vaccine derived from a serogroup B meningococcal isolate with constitutive FetA expression. PLoS One [Under review]."},{"issue":"9","key":"10.1016\/j.jinf.2015.05.006_bib42","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.vaccine.2005.09.043","article-title":"Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control","volume":"24","author":"Thornton","year":"2006","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.jinf.2015.05.006_bib43","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1128\/iai.54.3.710-713.1986","article-title":"Human immune response to iron-repressible outer membrane proteins of Neisseria meningitidis","volume":"54","author":"Black","year":"1986","journal-title":"Infect Immun"},{"issue":"5","key":"10.1016\/j.jinf.2015.05.006_bib44","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/INF.0b013e318195205e","article-title":"Immunogenicity and tolerability in infants of a New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine","volume":"28","author":"Wong","year":"2009","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"10.1016\/j.jinf.2015.05.006_bib45","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1128\/CVI.00304-10","volume":"18","author":"Kimura","year":"2011","journal-title":"Clin Vaccine Immunol"},{"issue":"8","key":"10.1016\/j.jinf.2015.05.006_bib46","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1128\/IAI.00466-06","article-title":"Comparison and correlation of Neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac","volume":"74","author":"Findlow","year":"2006","journal-title":"Infect Immun"},{"issue":"11","key":"10.1016\/j.jinf.2015.05.006_bib47","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.4161\/hv.25505","article-title":"Persistence of antibodies in adolescents 18\u201324 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine","volume":"9","author":"Santolaya","year":"2013","journal-title":"Hum Vaccines Immunother"},{"issue":"16","key":"10.1016\/j.jinf.2015.05.006_bib48","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1001\/jama.281.16.1520","article-title":"Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile","volume":"281","author":"Tappero","year":"1999","journal-title":"J Am Med Assoc"},{"issue":"11","key":"10.1016\/j.jinf.2015.05.006_bib49","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.1128\/IAI.71.11.6367-6371.2003","article-title":"Relative immunogenicity of PorA subtypes in a multivalent Neisseria meningitidis vaccine is not dependent on presentation form","volume":"71","author":"Luijkx","year":"2003","journal-title":"Infect Immun"},{"issue":"3","key":"10.1016\/j.jinf.2015.05.006_bib50","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1086\/514232","article-title":"Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland","volume":"177","author":"Perkins","year":"1998","journal-title":"J Infect Dis"},{"issue":"24","key":"10.1016\/j.jinf.2015.05.006_bib51","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1016\/j.vaccine.2012.03.011","article-title":"Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines","volume":"30","author":"Ladhani","year":"2012","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.jinf.2015.05.006_bib52","doi-asserted-by":"crossref","first-page":"e45349","DOI":"10.1371\/journal.pone.0045349","article-title":"Persistence of hyperinvasive meningococcal strain types during global spread as recorded in the PubMLST Database","volume":"7","author":"Watkins","year":"2012","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.jinf.2015.05.006_bib53","doi-asserted-by":"crossref","first-page":"5434","DOI":"10.1128\/IAI.00411-07","article-title":"Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis","volume":"75","author":"Weynants","year":"2007","journal-title":"Infect Immun"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445315001577?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445315001577?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:22:13Z","timestamp":1759008133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445315001577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0163445315001577"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2015.05.006","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2015.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}